The potential cost-effectiveness of novel cord blood therapies in children with autism spectrum disorder.

ABSTRACT:

Objective

To model the long-term clinical and economic outcomes of potential cord blood therapy in autism spectrum disorder (ASD).

Study design

Markov microsimulation of ASD over the lifespan was used to compare two strategies: 1) standard of care (SOC), including behavioral and educational interventions, and 2) novel cord blood (CB) intervention in addition to SOC. Input data reflecting behavioral outcomes included baseline Vineland Adaptive Behavior Scale (VABS-3), monthly VABS-3 changes, and CB intervention efficacy on adaptive behavior based on a randomized, placebo-controlled trial (DukeACT). Quality-adjusted life-years (QALYs) were correlated to VABS-3. Costs for children with ASD ($15,791, ages 2-17 years) and adults with ASD ($56,559, ages 18+ years), and the CB inte

SUBMITTER: Borre ED 

PROVIDER: S-EPMC10112778 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature